Mipasetamab uzoptirine is under clinical development by ADC Therapeutics and currently in Phase I for Osteosarcoma. According to GlobalData, Phase I drugs for Osteosarcoma have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Mipasetamab uzoptirine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mipasetamab uzoptirine overview
ADCT-601(BGB-601) is under development for the treatment of solid tumor, renal cell carcinoma, malignant fibrous histiocytoma. The drug candidate is an antibody drug conjugate conjugated using glycoconnect technology comprises of monoclonal antibody with a pyrrolobenzodiazepines (PBD) based warheads. The therapeutic candidate is administered through intravenous route. It is developed based on pyrrolobenzodiazepine (PBD) warhead technology. This technology develops antibody drug conjugated by linking pyrrolobenzodiazepine (PBD) dimers with tumor specific antibody. It acts by targeting cells expressing tyrosine protein kinase receptor UFO. It is also under development for relapsed and refractory triple-negative breast cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck squamous cell carcinoma, nasopharyngeal cancer, mesothelioma, non-small cell lung cancer, ovarian cancer, soft tissue sarcomas, leiomyosarcoma, liposarcoma, undifferentiated pleomorphic sarcoma, synovial sarcoma, bone sarcoma: Ewing's sarcoma, osteosarcoma, chondrosarcoma, fallopian tube cancer, primary peritoneal cancer, bladder cancer, cervical cancer, endometrial cancer and pancreatic cancer.
ADC Therapeutics overview
ADC Therapeutics, is a biotechnology company focused on the development and commercialization of antibody-drug conjugates (ADCs) to treat solid tumors and hematological cancers. It is investigating Loncastuximab Tesirine (Lonca), an ADC composed of a humanized monoclonal antibody against B-cell hematological tumors; and Camidanlumab Tesirine (Cami) for the treatment of solid tumors. It is also developing ADCT-602 drug for B-cell acute lymphoblastic leukemia; ADCT-601 targeting AXL in solid tumors; ADCT-901 against ovarian, triple-negative breast cancer and advanced solid tumors; and ADCT-701 drug targeting DLK-1 in neuroblastoma, hepatocellular carcinoma, small cell lung cancer, and acute myeloid leukemia. The company is a spin-off from Spirogen Ltd. ADC Therapeutics is headquartered in Lausanne, Switzerland.
For a complete picture of Mipasetamab uzoptirine’s drug-specific PTSR and LoA scores, buy the report here.